ArticleRespiratory medicine case reports2026
Versatility of High-Velocity Nasal Insufflation (HVNI) in respiratory weaning: A case series demonstrating three distinct clinical objectives.
Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-Velocity Nasal Insufflation (HVNI) is an advanced form of high-flow nasal therapy that delivers heated, humidified oxygen at high velocities through a small-bore nasal cannula, generating efficient extrathoracic dead space washout, mild positive end-expiratory pressure (PEEP), and enhanced patient comfort. While Non-Invasive Positive Pressure Ventilation (NiPPV) remains the reference treatment for acute hypercapnic respiratory failure, its use is frequently limited by patient intolerance. This case series presents three critically ill patients in whom HVNI was deployed during the respiratory weaning phase to achieve three distinct clinical objectives: (1) prophylactic stabilization to prevent post-extubation failure in a high-risk COPD patient; (2) rescue therapy for NiPPV intolerance with simultaneous airway clearance; and (3) bridging functional recovery during prolonged tracheostomy weaning. All patients achieved their targeted clinical endpoints without adverse events. These cases illustrate the clinical versatility of HVNI as an adaptable tool in the intensivist's armamentarium for individualized respiratory weaning strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.